Xenofon Baraliakos is an expert in Rheumatology at Universitätsklinik Marien Hospital Herne (Germany). As of November 2026, ScienceLeadR ranks Xenofon Baraliakos in the top 1% of experts worldwide for Ankylosis, Axial Spondyloarthritis and Spondylarthritis. Xenofon Baraliakos has authored 959 publications, the most recent in 2026, and is an investigator in 43 clinical trials, 5 of them ongoing. SLR score: 4,331 (community average: 125). How the SLR is computed.

LeadR Profile

Profile validated by the expert
4 331 ScienceLeadR Reputation 4331
Network Map

Rheumatology

Subspecialties: Dermatology - Internal Medicine - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2004 - 2026
Source: PubMed

Ruhr-Universität Bochum

- 2026

Rheumazentrum Ruhrgebiet

2004 - 2026

Ruhr University Bochum

2005 - 2026

Universitätsklinik Marien Hospital Herne

2012 - 2026

St. Josef-Hospital

2022 - 2026

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 959

Citations

Citations: 29 027 1st author: 202 Last author: 185 Unique author: 6


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Development of a specialised reproductive rheumatology consultation service: analysis of referral patterns across preconception, pregnancy, and lactation.
PMID 43046239 — rheumatology, pregnancy, lactation, therapeutics
BMC Rheumatol20260
Diffuse Idiopathic Skeletal Hyperostosis: The Evolution of a Disease Concept.
PMID 43024186 — osteogenesis, hyperostosis, diffuse idiopathic skeletal, hyperostosis, spine
Rheumatol Ther20260
Performance of a triage approach for identification of patients with inflammatory rheumatic and musculoskeletal diseases among rheumatology referrals.
PMID 42701083 — rheumatology, telephone, triage, rheumatic diseases, musculoskeletal diseases
Ann Rheum Dis20260
Instrument selection for the assessment of peripheral arthritis in axial and peripheral spondyloarthritis: an ASAS project.
PMID 42409723 — research design, biomedical research, arthritis, rheumatic diseases, research, axial spondyloarthritis
Ann Rheum Dis20260
Bimekizumab in Chinese patients with active radiographic axial spondyloarthritis: 52-week results from the phase 3 BE MOBILE 2 study.
PMID 42952004 — axial spondyloarthritis
Chin Med J (Engl)20261

Clinical Studies 43

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 20
Phase 2 9
N/A 7
Phase 4 4
Phase 2/Phase 3 2
Phase 1 1

By status:

Completed 30
Unknown 8
Active not recruiting 3
Recruiting 2

By type:

Interventional 37
Observational 6

By Monocentric/Multicentric:

monocentric 6
multicentric2to4 3
multicentric5to9 0
multicentricup10 34

Main Topics

Ongoing Clinical Trials

5 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
EAST 1 (ERAP inhibition in Axial Spondyloarthritis Trial 1)
2025-521315-39-00 — axial spondyloarthritis
Phase 1Recruiting2025
Study of CC 97540 (BMS 986353) CD19 CAR T Cells in Participants with Active SLE Despite Immunosuppressants (Breakfree SLE)
2024-519278-37-00 — cells, glucocorticoids, lupus nephritis, immunosuppressive agents, lupus erythematosus, systemic, nephritis, car-t cell
Phase 2Active not recruiting2025
Effects of IL 23 inhibition in patients with very early axial spondyloarthritis evidence for a true disease modification
2023-507718-28-00 — interleukin-23, axial spondyloarthritis
Phase 2Active not recruiting2024
Direct comparison between NSAIDs and biosimilar TNFa blockers in patients with axial spondyloarthritis
2024-513213-13-00 — anti-inflammatory agents, non-steroidal, therapeutics, biosimilar pharmaceuticals, axial spondyloarthritis
Phase 4Recruiting2025
A Study of Guselkumab Administered Subcutaneously in Bio naive Participants With Active Psoriatic Arthritis Axial Disease
NCT04929210 — injections, arthritis, psoriatic, safety, arthritis, injections, subcutaneous
Phase 4Active not recruiting2021

LeadR Networks

Main global connection map